Neuroprotective effects of short peptides derived from the Insulin-like growth factor 1

Neurochemistry International

Volumn 51, Issue 8, 2007, Pages 451-458

  Górecki, Dariusz C ^a   Beresewicz, Małgorzata ^b   Zabłocka, Barbara ^b  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Brain ischaemia; C terminal peptides; IGF 1; Neuroprotection

Indexed keywords

GROWTH HORMONE; HORMONE PRECURSOR; INSULIN LIKE GROWTH FACTOR 1EA; INSULIN LIKE GROWTH FACTOR 1EB; INSULIN LIKE GROWTH FACTOR 1EC; SOMATOMEDIN C; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; HUMAN; MITOGENESIS; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOGENS; NEUROPROTECTIVE AGENTS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1;

EID: 34848851582     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.04.030     Document Type: Short Survey

References (82)

1. Aberg N.D., Brywe K.G., and Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scientific World J. 6 (2006) 53-80
2. Adamo M.L., Neuenschwander S., LeRoith D., and Roberts Jr. C.T. Structure, expression, and regulation of the IGF-I gene. Adv. Exp. Med. Biol. 343 (1993) 1-11
3. Aperghis M., Johnson I.P., Cannon J., Yang S.Y., and Goldspink G. Different levels of neuroprotection by two insulin-like growth factor-I splice variants. Brain Res. 1009 (2004) 213-218
4. Bach M.A., Roberts Jr. C.T., Smith E.P., and LeRoith D. Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol. Endocrinol. 4 (1990) 899-904
5. Barton E.R. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J. Appl. Physiol. 100 (2006) 1778-1784
6. Batchelor D.C., Lin H., Wen J.Y., Keven C., Van Zijl P.L., Breier B.H., Gluckman P.D., and Thomas G.B. Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal. Biochem. 323 (2003) 156-163
7. Bergstedt K., and Wieloch T. Changes in insulin-like growth factor 1 receptor density after transient cerebral ischemia in the rat. Lack of protection against ischemic brain damage following injection of insulin-like growth factor 1. J. Cereb. Blood Flow Metab. 13 (1993) 895-898
8. Bondy C.A., and Cheng C.M. Signaling by insulin-like growth factor 1 in brain. Eur. J. Pharmacol. 490 (2004) 25-31
9. Carro E., and Torres-Aleman I. Serum insulin-like growth factor I in brain function. Keio J. Med. 55 (2006) 59-63
10. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21 (2001) 2-14
11. Clawson T.F., Vannucci S.J., Wang G.M., Seaman L.B., Yang X.L., and Lee W.H. Hypoxia-ischemia-induced apoptotic cell death correlates with IGF-I mRNA decrease in neonatal rat brain. Biol. Signals Recept. 8 (1999) 281-293
12. Connor B., and Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 27 (1998) 1-39
13. D'Ercole A.J., Ye P., Calikoglu A.S., and Gutierrez-Ospina G. The role of the insulin-like growth factors in the central nervous system. Mol. Neurobiol. 13 (1996) 227-255
14. Denti L., Annoni V., Cattadori E., Salvagnini M.A., Visioli S., Merli M.F., Corradi F., Ceresini G., Valenti G., Hoffman A.R., and Ceda G.P. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am. J. Med. 117 (2004) 312-317
15. Denti L., Banchini A., Caporotundo S., Giordano A., Rocci A., Merli M.F., Annoni V., Salimbeni I., Mazzoni S., Ablondi F., Valenti G., and Ceda G.P. IGF system in acute ischemic stroke. J. Endocrinol. Invest. 25 (2002) 55-56
16. Dimopoulou I., Kouyialis A.T., Orfanos S., Armaganidis A., Tzanela M., Thalassinos N., and Tsagarakis S. Endocrine alterations in critically ill patients with stroke during the early recovery period. Neurocrit. Care 3 (2005) 224-229
17. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
18. Dluzniewska J., Sarnowska A., Beresewicz M., Johnson I.P., Srai S.K.S., Ramesh B., Goldspink G., Gorecki D.C., and Zablocka B. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 19 (2005) 1896-1898
19. Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., and Musaro A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 168 (2005) 193-199
20. Domanska-Janik K., Buzanska L., Dluzniewska J., Kozlowska H., Sarnowska A., and Zablocka B. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Brain Res. Mol. Brain Res. 121 (2004) 50-59
21. Donahue C.P., Kosik K.S., and Shors T.J. Growth hormone is produced within the hippocampus where it responds to age, sex, and stress. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6031-6036
22. Drakenberg K., Ostenson C.G., and Sara V. Circulating forms and biological activity of intact and truncated insulin-like growth factor I in adult and neonatal rats. Acta Endocrinol. (Copenh) 123 (1990) 43-50
23. Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J. Endocrinol. 175 (2002) 41-54
24. Frago L.M., Paneda C., Dickson S.L., Hewson A.K., Argente J., and Chowen J.A. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology 143 (2002) 4113-4122
25. Giacobini M.M., Olson L., Hoffer B.J., and Sara V.R. Truncated IGF-1 exerts trophic effects on fetal brain tissue grafts. Exp. Neurol. 108 (1990) 33-37
26. Gleichmann M., Weller M., and Schulz J.B. Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons. Neurosci. Lett. 282 (2000) 69-72
27. Goldspink G. Age-related muscle loss and progressive dysfunction in mechanosensitive growth factor signaling. Ann. N. Y. Acad. Sci. 1019 (2004) 294-298
28. Guan J., Thomas G.B., Lin H., Mathai S., Bachelor D.C., George S., and Gluckman P.D. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 47 (2004) 892-903
29. Guan J., Waldvogel H.J., Faull R.L., Gluckman P.D., and Williams C.E. The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 89 (1999) 649-659
30. Guan J., Williams C.E., Skinner S.J., Mallard E.C., and Gluckman P.D. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology 137 (1996) 893-898
31. Hameed M., Lange K.H., Andersen J.L., Schjerling P., Kjaer M., Harridge S.D., and Goldspink G. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J. Physiol. 555 (2004) 231-240
32. Hameed M., Orrell R.W., Cobbold M., Goldspink G., and Harridge S.D.R. Clarification. J. Physiol. 549 (2003) 995-1995
33. Hayashi T., and Abe K. Ischemic neuronal cell death and organellae damage. Neurol. Res. 26 (2004) 827-834
34. Hwang I.K., Yoo K.Y., Park S.K., An S.J., Lee J.Y., Choi S.Y., Kang J.H., Kwon Y.G., Kang T.C., and Won M.H. Expression and changes of endogenous insulin-like growth factor-1 in neurons and glia in the gerbil hippocampus and dentate gyrus after ischemic insult. Neurochem. Int. 45 (2004) 149-156
35. Johnsen S.P., Hundborg H.H., Sorensen H.T., Orskov H., Tjonneland A., Overvad K., and Jorgensen J.O. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J. Clin. Endocrinol. Metab. 90 (2005) 5937-5941
36. Kawano T., Fukunaga K., Takeuchi Y., Morioka M., Yano S., Hamada J., Ushio Y., and Miyamoto E. Neuroprotective effect of sodium orthovanadate on delayed neuronal death after transient forebrain ischemia in gerbil hippocampus. J. Cereb. Blood Flow Metab. 21 (2001) 1268-1280
37. Kilic E., Kilic U., and Hermann D.M. TAT fusion proteins against ischemic stroke: current status and future perspectives. Front Biosci. 11 (2006) 1716-1721
38. Kim J.J., and Accili D. Signalling through IGF-I and insulin receptors: where is the specificity?. Growth Horm. IGF Res. 12 (2002) 84-90
39. Kurmasheva R.T., and Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim. Biophys. Acta 1766 (2006) 1-22
40. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92 (2005) 2097-2101
41. Lin S., Fan L.W., Pang Y., Rhodes P.G., Mitchell H.J., and Cai Z. IGF-1 protects oligodendrocyte progenitor cells and improves neurological functions following cerebral hypoxia-ischemia in the neonatal rat. Brain Res. 1063 1 (2005) 15-26
42. Liu X.F., Fawcett J.R., Thorne R.G., DeFor T.A., and Frey W.H. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 187 (2001) 91-97
43. Liu X.F., Fawcett J.R., Thorne R.G., and Frey W.H. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci. Lett. 308 (2001) 91-94
44. Lupu F., Terwilliger J.D., Lee K., Segre G.V., and Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229 (2001) 141-162
45. Mohammad Y.M., Divani A.A., Kirmani J.F., Harris-Lane P., and Qureshi A.I. Acute treatment for ischemic stroke in 2004. Emerg. Radiol. 11 (2004) 83-86
46. Mourkioti F., and Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol. 26 (2005) 535-542
47. Musaro A., Dobrowolny G., and Rosenthal N. The neuroprotective effects of a locally acting IGF-1 isoform. Exp. Gerontol. 42 1-2 (2007) 76-80
48. Nilsson-Hakansson L., Civalero I., Zhang X., Carlsson-Skwirut C., Sara V.R., and Nordberg A. Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain. Neuroreport 4 (1993) 1111-1114
49. O'Donnell S.L., Frederick T.J., Krady J.K., Vannucci S.J., and Wood T.L. IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia 39 (2002) 85-97
50. Oh Y., Muller H.L., Lee D.Y., Fielder P.J., and Rosenfeld R.G. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132 (1993) 1337-1344
51. Peruzzi F., Prisco M., Dews M., Salomoni P., Grassilli E., Romano G., Calabretta B., and Baserga R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell Biol. 19 (1999) 7203-7215
52. Peruzzi F., Prisco M., Morrione A., Valentinis B., and Baserga R. Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J. Biol. Chem. 276 (2001) 25990-25996
53. Read S.J., Parsons A.A., Harrison D.C., Philpott K., Kabnick K., O' Brien S., Clark S., Brawner M., Bates S., Gloger I., Legos J.J., and Barone F.C. Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J. Cereb. Blood Flow Metab. 21 (2001) 755-778
54. Russo V.C., Gluckman P.D., Feldman E.L., and Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26 (2005) 916-943
55. Sara V.R., Carlsson-Skwirut C., Andersson C., Hall E., Sjogren B., Holmgren A., and Jornvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4904-4907
56. Sara V.R., Carlsson-Skwirut C., Bergman T., Jornvall H., Roberts P.J., Crawford M., Hakansson L.N., Civalero I., and Nordberg A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Biochem. Biophys. Res. Commun. 165 (1989) 766-771
57. Sara V.R., Carlsson-Skwirut C., Drakenberg K., Giacobini M.B., Hakansson L., Mirmiran M., Nordberg A., Olson L., Reinecke M., and Stahlbom P.A. The biological role of truncated insulin-like growth factor-1 and the tripeptide GPE in the central nervous system. Ann. N. Y. Acad. Sci. 692 (1993) 183-191
58. Schabitz W.R., Hoffmann T.T., Heiland S., Kollmar R., Bardutzky J., Sommer C., and Schwab S. Delayed neuroprotective effect of insulin-like growth factor-i after experimental transient focal cerebral ischemia monitored with mri. Stroke 32 (2001) 1226-1233
59. Seigel G.M., Chiu L., and Paxhia A. Inhibition of neuroretinal cell death by insulin-like growth factor-1 and its analogs. Mol. Vis. 6 (2000) 157-163
60. Seigel G.M., Lupien S.B., Campbell L.M., and Ishii D.N. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. J. Diabetes Complications 20 (2006) 196-204
61. Shavlakadze T., White J., Hoh J.F., Rosenthal N., and Grounds M.D. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol. Ther. 10 (2004) 829-843
62. Shavlakadze T., Winn N., Rosenthal N., and Grounds M.D. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm. IGF Res. 15 (2005) 4-18
63. Siegfried J.M., Kasprzyk P.G., Treston A.M., Mulshine J.L., Quinn K.A., and Cuttitta F. A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 8107-8111
64. Singhal A.B., Lo E.H., Dalkara T., and Moskowitz M.A. Advances in stroke neuroprotection: hyperoxia and beyond. Neuroimaging Clin. N. Am. 15 (2005) 697-700
65. Sizonenko S.V., Sirimanne E.S., Williams C.E., and Gluckman P.D. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury. Brain Res. 922 (2001) 42-50
66. Smith L.E., Kopchick J.J., Chen W., Knapp J., Kinose F., Daley D., Foley E., Smith R.G., and Schaeffer J.M. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276 (1997) 1706-1709
67. Subramaniam S., Shahani N., Strelau J., Laliberte C., Brandt R., Kaplan D., and Unsicker K. Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway. J. Neurosci. 25 (2005) 2838-2852
68. Sun L.Y., and D'Ercole A.J. Insulin-like growth factor-I (IGF-I) stimulates histone H3 and H4 acetylation in the brain in vivo. Endocrinology (2006)
69. Switzer J.A., and Hess D.C. Statins in stroke: prevention, protection and recovery. Expert. Rev. Neurother. 6 (2006) 195-202
70. Tan D.S., Cook A., and Chew S.L. Nucleolar localization of an isoform of the IGF-I precursor. BMC Cell Biol. 3 (2002) 17
71. Torrado J., and Carrascosa C. Pharmacological characteristics of parenteral IGF-I administration. Curr. Pharm. Biotechnol. 4 (2003) 123-140
72. Tremblay R., Hewitt K., Lesiuk H., Mealing G., Morley P., and Durkin J.P. Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons. J. Neurochem. 72 (1999) 102-111
73. Valentinis B., Romano G., Peruzzi F., Morrione A., Prisco M., Soddu S., Cristofanelli B., Sacchi A., and Baserga R. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J. Biol. Chem. 274 (1999) 12423-12430
74. van Rijn M.J., Slooter A.J., Bos M.J., Catarino C.F., Koudstaal P.J., Hofman A., Breteler M.M., and van Duijn C.M. Insulin-like growth factor I promoter polymorphism, risk of stroke, and survival after stroke: the Rotterdam study. J. Neurol. Neurosurg. Psychiatry 77 (2006) 24-27
75. Vincent A.M., and Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res. 12 (2002) 193-197
76. Wahlgren N.G., and Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches. Cerebrovasc. Dis. 17 Suppl. 1 (2004) 153-166
77. Wang J.M., Hayashi T., Zhang W.R., Li F., Iwai M., and Abe K. Reduction of ischemic damage by application of insulin-like growth factor-1 in rat brain after transient ischemia. Acta Med. Okayama 55 (2001) 25-30
78. Wang J.M., Hayashi T., Zhang W.R., Sakai K., Shiro Y., and Abe K. Reduction of ischemic brain injury by topical application of insulin-like growth factor-I after transient middle cerebral artery occlusion in rats. Brain Res. 859 (2000) 381-385
79. Warren R.S., Yuan H., Matli M.R., Ferrara N., and Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 271 (1996) 29483-29488
80. Wilczak N., Elting J.W., Chesik D., Kema I.P., and De Keyser J. Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1. Stroke 37 (2006) 2368-2371
81. Winn N., Paul A., Musaro A., and Rosenthal N. Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. Cold Spring Harb. Symp. Quant. Biol. 67 (2002) 507-518
82. Yamamoto H., and Murphy L.J. Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action. J. Endocrinol. 146 (1995) 141-148